PepGen Inc. (PEPG)
After hours:
| Previous Close | 13.96 |
| Open | 14.08 |
| Bid | 13.37 x 100 |
| Ask | 13.88 x 100 |
| Day's Range | 13.60 - 14.15 |
| 52 Week Range | 3.72 - 17.51 |
| Volume | |
| Avg. Volume | 89,577 |
| Market Cap | 443.748M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Stifel 2024 CNS Days (Virtual) Tuesday, March 19, 2024, at 1:00 p.m. ET, Fireside Chat Needham Annual Healthcare Conference (Virtual) Monda
- GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutatio
- GlobeNewswire
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 – - CONNECT2-EDO51 Phase 2 clinical trial in DMD patients open in the U.K. - Company believes this study could potentially support accelerated approval - - FREEDOM-DM1 Phase 1 clinical trial enrolling DM1 patients with preliminary data for at least the 5 mg/kg dose cohort expected in the second half
